Provided by Tiger Trade Technology Pte. Ltd.

Takeda Pharmaceutical Co Ltd

18.35
+0.36502.03%
Volume:385.41K
Turnover:7.06M
Market Cap:58.38B
PE:-57.61
High:18.41
Open:18.23
Low:18.18
Close:17.98
52wk High:18.90
52wk Low:12.99
Shares:3.18B
Float Shares:3.09B
Volume Ratio:1.80
T/O Rate:0.01%
Dividend:0.63
Dividend Rate:3.41%
EPS(TTM):-0.3184
EPS(LYR):-0.3042
ROE:-2.26%
ROA:2.69%
PB:1.24
PE(LYR):-60.30

Loading ...

Takeda Canada Says Zasocitinib Shows Superiority to Deucravacitinib in Phase 3 Psoriasis Study

MT Newswires Live
·
Jun 23

Takeda Canada reports ‘positive’ results from Phase 3 study of zasocitinib

TIPRANKS
·
Jun 23

Takeda’s High-Stakes Overhaul: CEO Transition and Major Restructuring Raise Execution and Profitability Risks

TIPRANKS
·
Jun 18

Takeda presents additional results from oveporexton studies at SLEEP 2026

TIPRANKS
·
Jun 16

Takeda Pharmaceutical's Psoriasis Treatment Beats Competitor in Trial

MT Newswires Live
·
Jun 11

Takeda announces results for Phase 3 study of TAK-279

TIPRANKS
·
Jun 11

Takeda's Application for ENTYVIO IV Accepted by FDA in Pediatric Ulcerative Colitis and Crohn's Disease

MT Newswires Live
·
Jun 10

FDA accepts Takeda’s application for intravenous Entyvio

TIPRANKS
·
Jun 10

Takeda’s TAK-360 Narcolepsy Trial Moves Forward, Expanding Its Specialty CNS Pipeline

TIPRANKS
·
Jun 10

Takeda swings to FY25 net loss of JPY 152.1 billion; FY25 revenue falls 1.7% to JPY 4.51 trillion

Reuters
·
Jun 05

Takeda’s New Mezagitamab Trial Targets High-Risk Kidney Rejection, Bolstering Long-Term Pipeline Story

TIPRANKS
·
Jun 05

Takeda’s Real-World Maribavir Study in Argentina: What Investors Should Watch

TIPRANKS
·
Jun 05

TD Cowen Sticks to Its Buy Rating for Takeda Pharmaceutical Company (TAK)

TIPRANKS
·
Jun 04

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading

MT Newswires Live
·
Jun 01

Takeda Expands Maribavir Into Pediatric CMV, Extending Long-Term Upside Potential

TIPRANKS
·
May 23

Takeda Expands Real-World Data on OBIZUR, Supporting Its Rare Disease Strategy

TIPRANKS
·
May 23

Takeda Pharmaceutical Reportedly Found Liable in Constipation Drug Antitrust Case

MT Newswires Live
·
May 19

Jury finds Takeda caused about $885M in damages over generic delay, Reuters says

TIPRANKS
·
May 19

Jury Orders Takeda to Pay Hundreds of Millions in Antitrust Case, Bloomberg Reports

MT Newswires Live
·
May 19

Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says

TIPRANKS
·
May 19